Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.62 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | GLP1R | P43220 | 8/20 | 0.47 |
| ▸ | ALB | P02768 | 2/20 | 0.46 |
| ▸ | GNPAT | O15228 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25874948 | 1.00 | FOLH1 (0.62) | FOLH1NOD1EPHX2ADRA1AGLP1R | |
| SCHEMBL21099650 | 0.89 | NOD1 (0.57) | FOLH1NOD1EPHX2GLP1R | |
| SCHEMBL21099881 | 0.89 | NOD1 (0.57) | FOLH1NOD1EPHX2GLP1R | |
| SCHEMBL22271682 | 0.88 | GLP1R (0.58) | FOLH1NOD1EPHX2ADRA1AGLP1R | |
| SCHEMBL19786616 | 0.87 | NOD1 (0.69) | NOD1EPHX2GLP1R | |
| SCHEMBL20215725 | 0.87 | NOD1 (0.69) | NOD1EPHX2GLP1R | |
| SCHEMBL20215727 | 0.87 | NOD1 (0.69) | NOD1EPHX2GLP1R | |
| SCHEMBL16273259 | 0.87 | NOD1 (0.59) | FOLH1NOD1EPHX2GLP1R | |
| SCHEMBL20380824 | 0.87 | FOLH1 (0.58) | FOLH1NOD1EPHX2ADRA1AALB | |
| SCHEMBL20146943 | 0.86 | NOD1 (0.71) | NOD1EPHX2GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712434-B2 | Compound having anti-cancer effect, and preparation method therefor and use thereof | 3D MEDICINES (BEIJING) CO., LTD. (CN) | 2023-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712434-B2 | Compound having anti-cancer effect, and preparation method therefor and use thereof | HDGF, HGF, CYP4F11 | FOLH1 705/4885NOD1 1989/4885EPHX2 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.